Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2022-08-29 Annual Report
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
GTG Building Momentum on Commercial Plans 3 pages 171.6KB
Annual Report Classification · 95% confidence The document is an ASX Market Announcement titled 'Annual results – Momentum building on our commercial plans' and reports annual results for the year ended June 30, 2022. It contains detailed financial and operational information including revenue figures, business developments, scientific achievements, and strategic initiatives. The document is over 10,000 characters, indicating it is a substantive report rather than a brief announcement. The content aligns with a comprehensive yearly report covering company activity and full financial performance. Therefore, this document fits the definition of an Annual Report (10-K equivalent) rather than a brief earnings release or announcement of report publication.
2022-08-29 English
Corporate Governance Statement and Appendix 4G 27 pages 453.7KB
Governance Information Classification · 95% confidence The document is titled 'Corporate Governance Statement' and discusses the company's governance policies, board responsibilities, director appointments, diversity policies, committee structures, and related governance practices. It references the financial year ended 30 June 2022 and details the company's adherence to ASX Corporate Governance Principles and Recommendations. The content is focused on governance frameworks, board composition, and oversight rather than financial results or operational performance. There are no financial statements or earnings data present. This aligns with the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-08-29 English
GeneType Business Update Presentation 30 pages 2.2MB
Investor Presentation Classification · 95% confidence The document is a detailed business update presentation from Genetic Technologies Limited dated July 31, 2022. It includes strategic highlights, market overview, financial data such as revenue and cash balance, growth strategies, product and market information, and operational achievements. The content is structured as a presentation with slides, forward-looking statements, and business updates rather than a formal financial report or regulatory filing. There is no indication that this is an official annual or quarterly report, audit report, earnings release, or regulatory filing. The document is clearly a presentation aimed at investors or stakeholders to update them on business progress and strategy. Therefore, the most appropriate classification is Investor Presentation (IP).
2022-07-31 English
Q4 FY22 Results Milestones and Growth 8 pages 293.2KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX market announcement dated 28 July 2022, providing quarterly financial results and operational highlights for Genetic Technologies Limited for the quarter ended 30 June 2022 (Q4 FY22). It includes detailed cash flow statements, financial highlights, commercial updates, and an Appendix 4C quarterly cash flow report as required by ASX Listing Rule 4.7B. The content is comprehensive and includes actual financial data and analysis for the quarter, not just a brief announcement or a link to a report. The presence of the Appendix 4C cash flow report confirms this is a quarterly financial report. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2022-07-27 English
GeneType Risk Test Implemented in 9 Siles Health Clinics 2 pages 166.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX Market Announcement from Genetic Technologies Limited about a partnership to implement a genetic risk test in health clinics. It contains no financial statements, no regulatory form references, no voting results, no management or board changes, no earnings data, and no legal or capital structure updates. The content is a business update about a commercial partnership and product implementation. It is a typical corporate announcement to the market about business developments rather than a financial report or regulatory filing. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and miscellaneous filings that do not fit other specific categories.
2022-07-17 English
Completion of AffinityDNA Acquisition 2 pages 159.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX Market Announcement dated 14 July 2022, reporting the completion of an acquisition of AffinityDNA by Genetic Technologies Limited. It details the strategic rationale, business expansion, and operational integration related to the acquisition. There is no financial data, no regulatory certification, no voting results, no management or board changes, no earnings or interim report data, and no mention of a report being attached or published. The content is a corporate announcement about a capital transaction (acquisition) expanding the company's business. This fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes including acquisitions.
2022-07-13 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.